In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Vijay Tammara Biography and Net Worth

SVP of Ocugen

Dr. Tammara has over 20 years of leadership experience in global regulatory affairs, strategic drug development, and clinical strategy, contributing significantly to the approval of several products. His regulatory expertise spans both oral and injectable dosage forms of small molecules, peptides, proteins, monoclonal antibodies and vaccines. Dr. Tammara served previously as Vice President of Regulatory Affairs at Nuron Biotech Inc., Director of Regulatory Affairs at Merck & Co., Inc., Senior Associate Director at Wyeth Pharmaceuticals, and Assistant Director at Sanofi-Synthelabo in Worldwide Regulatory Affairs. Prior to industrial positions, Dr. Tammara held positions of increasing responsibility in the Office of Clinical Pharmacology and Biopharmaceutics at the U.S. FDA, where he received several awards, including the CDER Outstanding Reviewer Award, FDA Outstanding Achievement Award, and Awards of Excellence. Dr. Tammara received his Bachelor of Pharmacy from Kakatiya University, Masters in Pharmacy from Nagpur University, and Ph.D. in Pharmaceutics from the University of Louisiana, Monroe.

What is Vijay Tammara's net worth?: The estimated net worth of Vijay Tammara is at least $8,875.80 as of May 3rd, 2021. Dr. Tammara owns 9,000 shares of Ocugen stock worth more than $8,876 as of November 8th. This net worth evaluation does not reflect any other investments that Dr. Tammara may own. Learn More about Vijay Tammara's net worth.
How do I contact Vijay Tammara?: The corporate mailing address for Dr. Tammara and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Vijay Tammara's contact information.
Has Vijay Tammara been buying or selling shares of Ocugen?: Vijay Tammara has not been actively trading shares of Ocugen during the past quarter. Most recently, Vijay Tammara sold 4,317 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $16.00, for a transaction totalling $69,072.00. Following the completion of the sale, the senior vice president now directly owns 9,000 shares of the company's stock, valued at $144,000. Learn More on Vijay Tammara's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Vijay Tammara Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/3/2021	Sell	4,317	$16.00	$69,072.00	9,000
4/29/2021	Sell	29,991	$10.97	$329,001.27	9,000

Vijay Tammara Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $0.99

$0.95

$1.13

50 Day Range

MA: $1.03

$0.89

$1.30

2 Week Range

Now: $0.99

$0.35

$2.11

Volume

8,935,046 shs

Average Volume

6,157,143 shs

Market Capitalization

$283.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.75

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad